InGel Therapeutics, Inc.

📍 Boston, United States🗓 Founded 2022👥 8 employees💰 Last funded 2024
Biotechnology Research🌐 ingeltx.com
Website LinkedIn
InGel Therapeutics is Harvard-spinoff, regenerative medicine biotech leveraging novel neuroprotective mechanisms to stop retinal degeneration. Our beachhead indication is Retinitis Pigmentosa, with future expansion opportunities which include Dry-AMD and Glaucoma.
3
Total investors
3
Early stage
0
Mid stage
0
Late stage
2022
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
3
Investor activity2022–2024 · investors recorded per year
2022220241
Recent (last 2y)Earlier
Frequently asked questions
Who invested in InGel Therapeutics, Inc.?
InGel Therapeutics, Inc. has 3 investors on record on gritt.io, including 3 early-stage backers.
When did InGel Therapeutics, Inc. last raise funding?
The most recent investment in InGel Therapeutics, Inc. recorded on gritt.io was in 2024.
When was InGel Therapeutics, Inc. founded?
InGel Therapeutics, Inc. was founded in 2022.
What industry is InGel Therapeutics, Inc. in?
InGel Therapeutics, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is InGel Therapeutics, Inc. based?
InGel Therapeutics, Inc. is headquartered in Boston, United States.